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BACKGROUND. Histological evidence of pervasive inflammatory infiltrate has been noted in
both benign prostatic hyperplasia/hypertrophy (BPH) and prostate cancer (PCa). Cytokines
known to attract particular leukocyte subsets are secreted from prostatic stroma consequent to
aging and also frommalignant prostate epithelium. Therefore,wehypothesized that leukocytes
associated with either acute or chronic inflammation attracted to the prostate consequent to
aging or tumorigenesis may promote the abnormal cellular proliferation associated with BPH
and PCa.
METHODS. An in vitro system designed to mimic the human prostatic microenvironment
incorporating prostatic stroma (primary and immortalized prostate stromal fibroblasts),
epithelium (N15C6, BPH-1, LNCaP, and PC3 cells), and inflammatory infiltrate (HL-60 cells,
HH, andMolt-3 T-lymphocytes)wasdeveloped.ModifiedBoyden chamber assayswereused to
test the ability of prostate stromal and epithelial cells to attract leukocytes and to test the effect of
leukocytes on prostate cellular proliferation. Antibody arrays were used to identify leukocyte-
secreted cytokines mediating prostate cellular proliferation.
RESULTS. Leukocytic cellsmigrated towards both prostate stromal and epithelial cells. CD4þ
T-lymphocytes promoted the proliferation of both transformed and non-transformed prostate
epithelial cell lines tested,whereas CD8þT-lymphocytes aswell as dHL-60Mmacrophagic and
dHL-60N neutrophilic cells selectively promoted the proliferation of PCa cells.
CONCLUSIONS. The results of these studies show that inflammatory cells can be attracted to
the prostate tissue microenvironment and can selectively promote the proliferation of non-
transformed or transformed prostate epithelial cells, and are consistent with differential role(s)
for inflammatory infiltrate in the etiologies of benign andmalignant proliferative disease in the
prostate. Prostate 70: 377–389, 2010. # 2009 Wiley-Liss, Inc.
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INTRODUCTION
Immunohistochemical studies examining the histo-
pathology of benign prostatic hyperplasia/hypertro-
phy (BPH) and prostate cancer (PCa) have reported the
presence of pervasive inflammatory infiltrate compris-
ing leukocytes associated with acute inflammation,
chronic inflammation, or both. Inflammatory cells
comprising neutrophilic or lymphocytic infiltrates
were identified in 90% of transurethral resection of
the prostate (TURP) specimens from 80 patients
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diagnosed with BPH but no history of prostatitis or
prostatic infection [1]. Chronic lymphocytic infiltrate
was observed in association with areas of benign
hypertrophy and cancer in whole mount radical
prostatectomy specimens from a series of 40 consec-
utive patients with clinically localized PCa [2]. Chronic
inflammatory infiltrate was also detected in 30–60% of
1,197 randomly selected men with BPH as part of the
Medical Therapy of Prostatic Symptoms (MTOPS)
study. Patients with chronic inflammatory infiltrate
had larger prostate volumes and demonstrated signifi-
cantly more clinical progression and acute urinary
retention than those with no evidence of inflammation
[3]. Theyer et al. [4] reported that the majority of BPH
tissues examined demonstrated infiltration of various
T-cell lymphocyte populations typically associated
with chronic inflammation. Finally, a recent histolog-
ical study of sextant needle biopsies among men
diagnosed as biopsy-negative for cancer found high
levels of polymorphonuclear leukocytic infiltrates in all
93 patients examined but similar levels ofmononuclear
leukocytic infiltrate in only 7 of these same patients [5].
These studies suggest that leukocytes associated
with acute (e.g., neutrophilic) or chronic (e.g., mono-
cytic/macrophagic or lymphocytic) inflammation are
commonly observed in association with BPH and/or
PCa. However, it is not clear why leukocytes are
attracted to the prostate or whether they act to promote
or inhibit the abnormal proliferation of cells associated
with both BPH and PCa. Previous studies from our
laboratory have shown that cytokines known to attract
particular leukocyte subsets are secreted fromprostatic
stroma consequent to aging and also from malignant
prostate epithelium [6–8]. These observations suggest
that the prostatic microenvironment itself may attract
and possibly sequester circulating leukocytes. Depend-
ing upon the actual cell type, leukocytes associated
with either acute or chronic inflammatory responses
can contribute to the destruction or the proliferation
and repair of tissue. Acute inflammation is the initial
response of the body to harmful stimuli and is achieved
by the increased movement of granulocytes (primarily
neutrophils) from the blood into the injured tissues. A
cascade of biochemical events propagates andmatures
the inflammatory response, involving the local vascu-
lar and immune systems, and various cells within the
injured tissue. Chronic inflammation leads to a pro-
gressive shift in the type of cells which are present at
the site of inflammation towards macrophages, lym-
phocytes, and plasma cells, and is characterized by
simultaneous destruction and healing of the tissue
from the inflammatory process [9,10]. Taken together,
these observations suggest that leukocytes associated
with either acute or chronic inflammation may be
attracted to the prostate consequent to aging or
tumorigenesis. Moreover, once present, these inflam-
matory cells could act to either promote or attempt to
prevent the abnormal cellular proliferation associated
with BPH and PCa.
To begin to address these questions, we have
developed an in vitro system to mimic the human
prostaticmicroenvironment that incorporates prostatic
stroma, epithelium, and inflammatory infiltrate. The
studies presented here show that both aging stroma
and malignant prostatic epithelial cells secreted leu-
koattractants that were sufficient to induce the migra-
tion of neutrophils, macrophages, and CD4þ and
CD8þ T-lymphocytes towards prostate cells. More-
over, transformed prostate epithelial cells proliferated
in response to all leukocytic cell types tested, whereas
non-transformed prostate epithelial cells exhibited
mixed proliferative responses. The results of these
studies are consistent with a role for inflammatory
infiltrate in the promotion of both benign and malig-
nant proliferative disease in the prostate.
MATERIALSANDMETHODS
Cell Lines andCulture
N15C6 and BPH-1 cells are non-transformed pros-
tate epithelial cells and grow continuously in culture
but do not form colonies in soft agar or tumors
in immunocompromised mice [11–13]. N15C6 were
maintained in 5% HIE media [Ham’s F12 (Mediatech,
Inc., Herndon, Virginia)] with 5% FBS (Life Technolo-
gies, Inc.), 5 mg/ml insulin, 10 ng/ml EGF, 1 mg/ml
hydrocortisone (Sigma–Aldrich, St. Louis, MO) or in
defined serum-free (SF) media supplemented to 5mM
ethanolamine (Sigma–Aldrich), 10mMHEPES (Sigma–
Aldrich), 5 mg/ml transferrin (Sigma–Aldrich), 10 mM
3,30,5-triiodo-L-thyronine (Sigma–Aldrich), 50mMsodium
selenite (Sigma–Aldrich), 0.1% BSA (JRH Biosciences,
Lenexa, KS), 0.05mg/ml gentamycin (Invitrogen,
Carlsbad, CA), and 0.5mg/L fungizone, 50mg/L
gentamycin, and 0.52mg/L plasmocin (Cambrex Bio-
science, Walkersville, MD) [11,12]. BPH-1 cells were
maintained in 10% RPMI or SF RPMI (0.1% BSA) and
antibiotics as described above [13]. The androgen-
sensitive LNCaP and 22Rv1 and androgen-insensitive
PC3 and DU145 transformed prostate epithelial cell
lines were maintained in 10% RPMI media or SF RPMI
[14–17]. N1 immortalized prostate stromal fibroblasts
were maintained in 5% HIE media or SF HIE [8]. PF1,
PF2, PF3, PF4, and PF5 primary stromal fibroblast
cultures were derived from peri-urethral prostate
tissues histologically assessed as free from cancer,
andwere cultured andmaintained in 5%HIE or SFHIE
as described previously [6]. HL-60 cells, a promyelo-
cytic leukemic cell line, was acquired from the
American Type Culture Collection (ATCC# CCL240)
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andwasmaintained in 10% RPMImedia with 1% Pen/
Strep [18]. HL-60 cells were promoted to terminally
differentiate along agranulocytic (neutrophilic) lineage
(dHL-60N) through treatment with 1.25% dimethyl
sulfoxide (DMSO) for 14 days or along a monocytic/
macrophagic lineage (dHL-60M) through treatment
with 10 nM phorbol myristic acid (PMA) for 18 hr [19].
T-lymphocytic cell lines HH (CD4þ) and Molt-3
(predominantly CD8þ) were acquired from the
American Type Culture Collection (ATCC# CRL-
2105; CRL-1552), respectively and maintained in 10%
RPMI media (Invitrogen #A10491) with 1% Pen/Strep
[20–22]. All cell lines were cultured in a humidified 5%
CO2 atmosphere at 378C.
ELISAAssays
Protein levels were measured by sandwich ELISA
using SFmedia conditioned for 24 hr by 1 106prostate
cells or complete leukocyte-conditionedmedia. ELISAs
were conducted on media aspirated after centrifuga-
tion to pellet cells. For prostate cells, the conditioned
SF media was first concentrated using Centriplus
centrifugal filters (Millipore, Billerica, MA) with a
3 kDa molecular weight cutoff. ELISA was performed
using Human CXCL5/ENA-78 DuoSet DY254, IL-8/
CXCL8 DuoSet DY208, CCL2/MCP-1 DuoSet DY279,
CCL5/RANTES DuoSet DY278, or CXCL12/SDF-1
alpha capture antibody MAB350, detection antibody
BAF310, and standard 350-NS ELISA reagents (R&D
Systems,Minneapolis, MN). For all ELISAs, a standard
curve was generated with the provided standards and
utilized to calculate the quantity of chemokine in the
sample tested. All reactions were performed in
duplicate, and the resulting valueswere averaged [6,8].
ProliferationAssay
N15C6, BPH-1, and PC3 cells were plated at 10,000
cells/well and LNCaP cells were plated at 25,000 cells/
well in quadruplicate per time point and allowed to
adhere for 24 hr. 50,000 dHL-60N, dHL-60M, HH, or
Molt-3 cells were added to each well and the cell
mixtures incubated for an additional 24 hr. At the end
of the incubation period the dHL-60N, dHL-60M, HH,
or Molt-3 cells were removed by gentle aspiration and
the adhered epithelial cells trypsinized and counted as
described previously [6]. Each proliferation assay was
repeated three times, and cell numbers averaged and
standarddeviationswere calculated for each timepoint
to permit statistical analysis.
MigrationAssays
For peripheral blood mononuclear cell (PBMC)
migration studies, leukocytes were isolated from
venous blood from healthy donors and depleted of
monocytes by adherence to plastic for 2 hr. Monocyte-
depleted white blood cells (1 106 cells/ml) were
fluorescently labeled with 20mM of 2,7-bis-(2-carbox-
yethyl)-5-carboxyfluorescein acetoxymethyl (BCECF
AM) (Molecular Probes, Eugene, OR) according to the
manufacturers directions. The cells were washed and
resuspended at 1 106 cells/ml in SF RPMImedia, and
1 105 labeled cells in 100 ml were added to the upper
chamber of a 24-well Transwell chemotaxis insert with
pore size of 5 mm (Corning, Corning, NY). The lower
chambers contained 200 ml SF RPMI (as control), SF
HIE, or SF HIE that was conditioned for 48 hr by four
independently derived cultures of primary prostate
stromal fibroblasts and concentrated as described
above. After 30 and 60min, the number of fluorescently
labeled migrating cells into the lower chamber was
determined at 485/535 nM wavelength using a Tecan
GENios plate-reader (Phenix, Austria). The results
were expressed as the average fold increase of the
number of cells migrating toward lower divided by the
number of cells migrating toward the control wells (SF
RPMI) [23,24].
For all other studies, an in vitro model system was
utilized composed of leukocytes (dHL-60N, dHL-60M,
HH, or Molt-3 T-lymphocytes), non-transformed
(N15C6, BPH-1) and transformed (LNCaP, PC3)
prostate epithelial cells, and non-transformed immor-
talized (N1) or primary (PF1) prostate stromal fibro-
blasts. Themigration assays utilized a Boyden chamber
system (BD Biosciences, San Jose, CA)with 3 mm (dHL-
60N, dHL-60N) or 8 mm (dHL-60M, HH, Molt-3)
membranes. For each assay, 375,000 dHL-60N or
dHL-60M, or 300,000 HH or Molt-3, cells were seeded
into the upper chamber and leukocyte chemotaxis was
measured after 4 hr of exposure to chemoattractants
(cytokines, plated cells, or fibroblast-conditioned
media) or control vehicle using modified Boyden
chamber assays (BD Biosciences). All experiments
acquired replicate or triplicate measures and were
graphed as averaged values across multiple assays.
CytokineArrays
1 106 dHL-60N, dHL-60M, HH, or Molt-3 cells
were incubated in 5ml of complete media for 24 hr.
Cells were removed by centrifugation and 1ml of the
supernatant was incubated with the RayBio1 Human
Cytokine Antibody Array 5 (Cat# AAH-CYT-5) (Ray-
biotech, Norcrosse, GA). Arrays were processed
according to manufacturer’s protocols and evaluated
using software provided by the manufacturer.
Statistical Analysis
Data were averaged and standard deviations calcu-
lated for graphical depiction and statistical analysis by
The Prostate
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t-test or analysis of variance with P< 0.05 considered
statistically significant.
RESULTS
ProstateCells Secrete Leukotactic Cytokines
Previous studies from our laboratory have demon-
strated the secretion of the CXC-type chemokine
CXCL12 (SDF-1) by prostate stromal fibroblasts and
CXCL5 (ENA-78) by both fibroblasts and prostate
epithelial cells [6–8]. CXCL12 and CCL2 (MCP-1) are
chemotactic for macrophages whereas CXCL8 (IL-8)
and CXCL5 are strongly chemotactic for neutrophils
[25,26]. Therefore, we tested whether several com-
monly available prostate-derived cells secreted meas-
urable levels of these four cytokines. As summarized in
Table I, sandwich ELISA measurements taken from
24 hr conditioned SF media demonstrated similar
levels of secreted CXCL5 and CXCL8 protein for all
cell lines tested,with themost robust secretiondetected
for N1 immortalized and PF1 primary prostate stromal
fibroblasts as well as BPH-1 non-transformed and
PC3 and DU145 transformed prostate epithelial cells.
Robust CCL2 secretion was detected for PF1 primary
prostate stromal fibroblasts with weaker expression
detected for N1 immortalized prostate fibroblasts and
for BPH-1 prostate epithelial. Consistent with its role
as a stromally derived cytokine, CXCL12 secretion
was detected only for N1 and PF1 prostate stromal
fibroblasts. Taken together, these data suggested that
CXCL5 and CXCL8, both strongly chemotactic for
neutrophils, were secreted robustly by both stromally
derived and epithelial-derived prostate cells, whereas
CCL2 was secreted differentially by prostate epithelial
and fibroblast cells, and CXCL12 exclusively by
prostate stromal fibroblasts.
InVitroModel for Leukocyte Chemotaxis
In order to accurately mimic the prostate tissue
microenvironment, it was first necessary to test
whether the cytokine levels secreted by prostate cells
was sufficient to induce leukocytic migration. These
studies first focused on examining neutrophil and
macrophage chemotaxis towards CXCL5 secreted
by both prostate stromal and epithelial cells, and
CXCL12 secreted solely by prostate stromal fibroblasts.
For these assays, pro-myelocytic HL-60 cells were
promoted to terminally differentiate along a granulo-
cytic (neutrophilic) lineage (dHL-60N) through treat-
ment with 1.25% DMSO for 14 days or along a
monocytic/macrophagic lineage (dHL-60M) through
treatment with 10 nM PMA for 18 hr [19] (Fig. 1A).
Incubation of complete media or complete media
conditioned by HL-60, dHL-60N, or dHL-60M with
the RayBio1 Human Cytokine Antibody Array con-
firmed cellular differentiation, as the proteins secreted
by HL-60, dHL-60N, and dHL-60M differed signifi-
cantly from each other and from the culture media
alone (Fig. 1B,C). In particular, dHL-60M secreted high
levels of several CCL-type cytokines, including CCL2
(MCP-1), CCL4 (MIP-1beta), CCL5 (RANTES), and
CCL24 (Eotaxin-3). dHL-60M also secreted high levels
of the CXC-type cytokines CXCL5 (ENA-78) and
CXCL8 (IL-8), as well as TIMP-1 and Osteopontin.
dHL-60N were less secretory than dHL-60M and
secreted high levels only of CCL2, CCL4, CXCL8, and
TIMP-1. None of these proteins were appreciably
secreted by undifferentiated HL-60 cells, and were
not present in the culture media alone.
To study dHL-60N and dHL-60M chemotaxis, a
24-well Boyden chamber plate was supplementedwith
complete media containing vehicle, known chemo-
attractant cytokine (CXCL8 for dHL-60N or CCL2 for
dHL-60M), or increasing concentrations of CXCL5 or
CXCL12 in completemedia. Porous inserts were added
to the plate and seeded with 375,000 dHL-60N or dHL-
60M in complete media (Fig. 2A–D). After 4 hr
incubation, the number of dHL-60N or dHL-60M cells
that migrated through the membranes and into the
bottom chamber was counted. These assays showed
that 50% more dHL-60N migrated towards CXCL8
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TABLE I. Prostate Cell Chemokine Secretion
CXCL5 (ENA-78) CXCL8 (IL-8) CXCL12 (SDF-1) CCL2 (MCP-1)
N15C6 9 (1.1) 10 (0.8) 0 0
BPH-1 565 (70.4) 81 (5.5) 0 18 (3.2)
22RV1 0 0 0 0
LNCaP 0 0 0 0
PC3 47 (3.4) 34 (3.3) 0 0
DU145 28 (6.3) 94 (6.3) 0 0
N1 1,935 (107.3) 311 (24.1) 28 (5.5) 3 (0.1)
PF1 1,090 (40) 681 (58.7) 32 (0.1) 875 (177.5)
pg/ml/million cells (standard deviation from the mean).
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and 25% more towards 100–1,000 pg/ml CXCL5
compared to vehicle (Fig. 2E) but that dHL-60N did
not migrate towards CXCL12 (Fig. 2F). Thus, as
expected, the dHL-60N cells differentiated along a
neutrophilic lineage demonstrated preferential migra-
tion towards the neutrophilic chemotaxic chemokines,
CXCL5 and CXCL8. dHL-60M cells migrated robustly
towards CCL2, 100–1,000 pg/ml CXCL5 (Fig. 2E), and
10–100 pg/ml CXCL12 at levels two- to threefold
higher than that observed for vehicle (Fig. 2F). Thus,
the dHL-60M cells differentiated along a macrophagic
lineage demonstrated preferential migration towards
the macrophagic chemokine CCL2 and CXCL12. dHL-
60M also migrated towards CXCL5 which, though
typically considered a neutrophilic chemokine, has
been shown to be a chemoattractant for macrophagic
leukocytes as well [27,28]. The results of these studies
also suggested that dHL-60M were more mobile than
dHL-60N, as they migrated more robustly towards the
strongly macrophilic cytokine, CCL2, than did dHL-
60N towards the strongly neutrophilic cytokines,
CXCL5 and CXCL8 (Fig. 2E,F). Taken together, these
studies showed that HL-60 cells differentiated along
neutrophilic or macrophagic lineages trafficked
towards chemokines at levels similar to those secreted
by prostate stromal fibroblasts and both non-trans-
formed and transformed prostate epithelial cells.
Modulation of Leukocyte Chemotaxisby Prostate
Stromaland Epithelial Cells
Previous studies from our laboratory demonstrated
that prostatic stromal fibroblasts and epithelial
cells secrete several leukotactic proteins [6–8]. ELISA
demonstrated robust secretion of leukotactic CXCL5,
CXCL8, CXCL12, and CCL2 by both N1 immortalized
and PF1 primary cultured prostate stromal fibroblasts
and of CXCL5, CXCL8, and CCL2 by several non-
transformed and transformed prostate epithelial cell
lines (Table I). Therefore, we next examined whether
prostate epithelial and stromal fibroblast cells secreted
these cytokines at levels sufficient for leukocytic
chemotaxis. As shown in Figure 3, >2-fold more
dHL-60N or dHL-60M cells migrated towards N15C6
The Prostate
Fig. 1. Terminally differentiated neutrophils (dHL-60N) andmacrophages (dHL-60M) secrete chemotactic factors.A: Photomicrographs
(400) ofHL-60promyelocytic cellmorphologycompared to thatof the same cellspromoted to terminallydifferentiate along agranulocytic
(neutrophilic; dHL-60N) lineage or along a monocytic/macrophagic (dHL-60M) lineage. B: Autoradiograph of RayBio1 Human Cytokine
AntibodyArrayafter incubationwithcompletemedia ormedia conditionedbyHL-60, dHL-60N,ordHL-60Mcells.Fourof themorerobustly
dHL-60NordHL-60Msecretedcytokines (CCL2,CCL5,CXCL8,TIMP-1) areindicated.‘‘P’’specifiespositive controland‘‘N’’specifiesnegative
control.C:ChartdisplayingcytokinesdetectedinmediaconditionedbyHL-60,dHL-60N,dHL-60Morinunconditionedcompletemedia.
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or BPH-1 prostate epithelial cells compared to migra-
tion towards vehicle-supplemented media alone. The
addition of CCL2 did not augment dHL-60M chemo-
taxis above those levels observed in the presence
(Fig. 3B) or absence (Fig. 2E,F) of prostate epithelial
cells, suggesting that the prostate epithelial cells alone
provided sufficient chemoattractant to induce high
levels of dHL-60 migration. In contrast, dHL-60N
migrated much more robustly in the presence
(Fig. 3A) of prostate epithelial cells than in their
absence (Fig. 2E,F). The addition of CXCL8 further
augmented dHL-60N chemotaxis (Fig. 3A).
The migration of both dHL-60M and dHL-60N cells
was significantly enhanced in the presence of N15C6
or BPH-1 prostate epithelial cells (Fig. 3A,B). These
studies showed that prostate epithelial cells secreted
sufficient chemoattractants to promote leukocytic
chemotaxis.
It is likely that infiltrating leukocytes interact with
multiple cell types within the human prostate. There-
fore, an initial test of how two common cell types in the
prostate, stromal fibroblasts, and glandular epithelial
cells, may modulate leukocytic infiltration was con-
ducted. For these experiments, N15C6 or BPH-1 cells
were seeded as described above, the media was
aspirated, then replaced with media conditioned by
a transient culture of PF1 primary prostate stromal
fibroblasts. These studies showed that dHL-60N
migration towards N15C6 prostate epithelial cells,
and dHL-60M migration towards BPH-1 prostate
epithelial cells, was negatively modulated by media
conditioned by PF1 primary prostate fibroblasts
(Fig. 3A,B). These data suggested that interactions be-
tween prostate epithelial and stromal fibroblast cells
could differentially modulate leukocytic chemotaxis.
The specificity of dHL-60N chemotaxis towards
prostate epithelial cells was tested by plating non-
transformed N15C6 or transformed PC3 prostate
epithelial cells in the bottom chambers as described
above, then pre-treating the cells for 1 hr with 1 mg/ml
antibodies against the chemokine receptors CXCR2 or
CXCR4, or the control IgG. dHL-60N cells were added
and the number of cells which migrated through the
membranewas counted 4 hr later. As seen in Figure 3C,
>2-fold more dHL-60N migrated into the bottom
chambers seeded with N15C6 or PC3 cells compared
The Prostate
Fig. 2. CXCL5 and CXCL12 are chemotactic for dHL-60N and dHL-60M. Diagram showing experimental schema for modified Boyden
Chamber assays.Leukocyteswere seededinto theupper chamber and separated from thebottomchamberby a porous (3mmfordHL-60N,
8mmfordHL-60Mmembrane).Vehicle,chemokine,orprostatecells(epithelialor fibroblast)wereseededinto thelowerchamber.Assaysmeas-
uredmovementofleukocytesplatedinupperchamber throughthemembranetowardschemoattractantsinthebottomchamberaswellas the
proliferativeresponse of cells platedin thebottomchamber.A:Basal levels of chemotaxis towards vehicle inbottomchamber (negative con-
trol); (B) chemotaxis towards chemokine in bottom chamber (positive control); (C) basal levels of prostate epithelial cell proliferation;
(D) chemotaxis of leukocytes towards cells inbottomchamber;prostate epithelial cellproliferation in thepresence of leukoctyes.E: Chemo-
tacticmigrationofdHL-60NordHL-60Mcells towardsincreasingconcentrationsofCXCL5.CCL2isincludedasapositivecontrolfordHL-60M;
CXCL8 as a positive control for dHL-60N.CXCL5 is strongly chemotactic for dHL-60M, less so for dHL-60N.F: Chemotactic migration of
dHL-60N or dHL-60M cells towards increasing concentrations of CXCL12.CCL2 is included as a positive control for dHL-60M; CXCL8 as
a positive control for dHL-60N. CXCL12 is strongly chemotactic for dHL-60M, less so for dHL-60N. * Indicates significantly (P< 0.05)
higher levels ofcellularmigrationcomparedtovehicle control.
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to unseeded wells. However, dHL-60N migration
towards N15C6 cells was significantly inhibited by
pre-treatment with antibody against CXCR2, though
not by pre-treatment with antibody against CXCR4
or IgG. Pre-treatment of PC3 cells with any of the
antibodies tested did not inhibit dHL-60N migration.
These studies suggested that one or more CXCR2
agonists mediating dHL-60N migration were likely
secreted at higher levels by PC3 compared to N15C6
cells.
dHL-60NanddHL-60MPromote the Proliferation
of Transformed Prostate Epithelial Cells
Although both dHL-60N and dHL-60M were
attracted to N15C6 and BPH-1 cells, it was unclear
whether proteins secreted by these leukocytes would
promote, repress, or have no effect, on prostate
epithelial cell proliferation. To test this, non-trans-
formed N15C6 or BPH-1, or transformed LNCaP or
PC3, prostate epithelial cells were co-cultured for 24 hr
with media (as control) or with dHL-60N or dHL-60M
cells, then counted. These studies showed that dHL-
60M promoted the proliferation of both LNCaP and
PC3 transformed prostate epithelial cells, whereas
dHL-60N cells promoted the proliferation of PC3 cells
only. The proliferation of non-transformed N15C6 and
BPH-1 was unaffected by the presence or absence of
dHL-60N or dHL-60M cells (Fig. 3D). Taken together,
this data suggested that myeloid lineage leukocyte
dHL-60N and dHL-60M cells selectively promoted the
proliferation of transformed, but not non-transformed,
prostate epithelial cells.
HHandMolt-3 T-Lymphocytes Promote the
ProliferationofTransformedProstate Epithelial Cells
Several studies have demonstrated the infiltration
of human prostate tissues by CD4þ and/or CD8þ
T-lymphocytes. The studies described above suggested
that myeloid-derived leukocytes can modulate the
proliferation of prostate epithelial cells. In order to test
whether lymphoid-derived leukocytes might also be
capable of modulating prostate epithelial cell prolifer-
ation, two additional cell lines, the T lymphocytic
CD4þHH and predominantly CD8þMolt-3 cells were
incorporated into the in vitro model. Incubation of
culture media or culture media conditioned by HH or
The Prostate
Fig. 3. dHL-60NanddHL-60Mchemotaxis andproliferationare
promotedbyprostate stromal and epithelial cells.A: Chemotactic
migrationofdHL-60Ncells towardsvehicle(setasequal to onefold)
or towards N15C6 or BPH-1 prostate epithelial cells seeded into
chambers containingcompletemediawithvehicle, 5ng/mlCXCL8,
or complete media conditioned by PF1 primary prostate stromal
fibroblasts.PF1conditionedmedia negativelymodulated themigra-
tionofdHL-60NtowardsN15C6,butnotBPH-1,cells.*Indicatessig-
nificantly higher and# indicates significantly lower levels of cellular
migration (P< 0.05). B: Chemotactic migration of dHL-60M cells
towardsN15C6orBPH-1prostateepithelialcells seededinto cham-
bers containing complete media with vehicle (set as equal to one-
fold), 2 ng/mlCCL2, or towards completemedia conditionedbyPF1
primary prostate stromal fibroblasts. PF1conditionedmedia nega-
tivelymodulatedthemigrationofdHL-60MtowardsBPH-1,butnot
N15C6, cells. * Indicates significantly higher and # indicates signifi-
cantlylowerlevelsofcellularmigration(P< 0.05).C:N15C6or trans-
formed PC3 prostate epithelial cells were seeded into chambers
pre-treatedwith antibody against CXCR2,CXCR4, or an IgG con-
trol.Chemotacticmigration of dHL-60N cells towardsN15C6 cells
was inhibitedby pre-treatmentwith antibody against CXCR2, but
not by pre-treatment with antibodies against CXCR4 or the IgG
control.ChemotacticmigrationofdHL-60NtowardsPC3cellswas
not inhibited by pre-treatment. * Indicates significantly higher and
# indicates significantly lower levels of cellularmigration (P< 0.05).
D: The proliferation of transformed PC3 and LNCaP or non-
transformedN15C6 or BPH-1cells wasmeasured after 24hr expo-
sure to dHL-60N (left) or dHL-60M (right) or vehicle. PC3 cells
proliferated significantly in response to the presence of dHL-60N
cells, whereas both PC3 and LNCaP cells proliferated significantly
inresponse to thepresenceofdHL-60Mcells (*P< 0.05).
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Molt-3 cells with the RayBio1 Human Cytokine Anti-
body Array demonstrated similar secretory profiles for
both T-lymphocyte derived cell lines (Fig. 4A,B). As
noted above, previous studies from our laboratory
demonstrated that prostatic stromal fibroblasts and
epithelial cells secrete several leukotactic proteins [6–8]
(Table I). Therefore, we sought to determine whether
PBMCs comprising predominantly T-lymphocytes
would demonstrate chemotaxis towards cultured
prostate stromal fibroblasts and/or epithelial cells.
The results of these studies showed that media
conditioned by primary prostate stromal fibroblasts
derived from four different individuals attracted 20–
60%more PBMCs than unconditionedmedia (Fig. 4C).
Migration assays similar to those described above
using modified Boyden chambers demonstrated
>3-fold migration of HH or Molt-3 cells towards PC3
or N15C6 cells (Fig. 4D). To test whether lymphoid-
derived leukocytes could modulate prostate epithelial
cells proliferation, non-transformed N15C6 or BPH-1,
or transformed LNCaP or PC3, prostate epithelial cells
were co-cultured for 24 hr with media (as control) or
with HH or Molt-3 cells (or no cells, as a control), then
counted. These studies showed that bothHHandMolt-
3 T-lymphocytes promoted the proliferation of PC3
transformed prostate epithelial cells, whereas only HH
T-lymphocytes promoted the proliferation of N15C6
and, to a lesser extent, BPH-1 cells (Fig. 5A). Taken
together, this data suggested that lymphoid lineage
leukocyte HH and Molt-3 cells promoted the prolife-
ration of both non-transformed and transformed
prostate epithelial cells.
dHL-60N and dHL-60M cells are terminally differ-
entiated myeloid cells, and therefore proliferate poorly
after differentiation. Therefore, the reciprocal effect, if
any, of prostate epithelial cells on the proliferation of
thesemyeloid lineage leukocytes could not be assessed.
However, this was not the case for the lymphoid-
derivedHHandMolt-3 leukocytes. The proliferation of
these cells was assessed after 24 and 96 hr of growth in
the presence or absence of each of the four prostate
epithelial cell lines used in these studies. These studies
showed that HH T-lymphocytes proliferated signifi-
cantly better in the presence of non-transformed BPH-1
as well as transformed LNCaP and PC3 cells than
in their absence, but were growth-inhibited in the
presence of non-transformed N15C6 cells. Molt-3
T-lymphocytes proliferated significantly better in the
presence of all four prostate epithelial cell lines tested
than in their absence (Fig. 5B). These studies showed
that the proliferation of HH and Molt-3 lymphoid-
derived leukocytes was largely promoted by inter-
action with both non-transformed and transformed
prostate epithelial cells.
As noted above, the myeloid-lineage dHL-60N
and dHL-60M both promoted the proliferation of
transformed PC3 cells (Fig. 3D). In contrast, the HH
T-lymphocytes promoted the proliferation of both
non-transformed N15C6 and transformed PC3 cells
The Prostate
Fig. 4. Prostate stromal fibroblast and epithelial cells promote
T-lymphocyte chemotaxis.A: Autoradiograph ofRayBio1Human
CytokineAntibodyArray after incubationwith completemedia or
media conditionedbyCD4þHHandCD8þMolt-3T-lymphocytes.
Two of themorerobustly secretedcytokines,CCL5andTIMP-1, are
indicated. ‘‘P’’ specifies positive control and ‘‘N’’ specifies negative
control. B: Chart displaying cytokines detected in media condi-
tionedbyCD4þHHandCD8þMolt-3T-lymphocytes or inuncon-
ditioned complete media. C: Chemotactic migration of largely
T-lymphocytic PBMCs towards SF RPMI (control), serum-free HIE
(SF)media,orSFmediaconditionedbyPF2,PF3,PF4,orPF5primary
prostate stromal fibroblastculturesmeasuredat 30and60minwas




cells towards vehicle (set equal to onefold), towardsN15C6 or PC3
prostate epithelial cells seeded into chambers containing complete
media with vehicle or with 5ng/ml CXCL8. Both CD4þ HH and
CD8þMolt-3 T-lymphocytesmigrated robustly towards the pros-
tate epithelial cells. No additive migratory effect was observed
for wells containing both prostate epithelial cells and CXCL8
(*P< 0.05).
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whereasMolt-3 T-lymphocytes promoted only PC3 cell
proliferation (Fig. 5A). The secretomes of these four
leukocytic cell types differed substantially, suggesting
that the secretion of different cytokines by these cells
might mediate epithelial proliferative responses
(Figs. 1 and 4). To address this, the secreted proteins
levels of specific cytokines identified as highly up-
regulated by the leukocytic cells were assessed by
ELISA. As shown in Table II, the high levels of CCL5
expression by dHL-60M and HH T-lymphocytes
detected by antibody array was confirmed and quanti-
fied at 401 pg/ml/million cells. High levels of
CCL2 secretion by dHL-60N and dHL-60M cells was
also confirmed and quantified at 272 and 352, respec-
tively, pg/ml/million cells. Both N15C6 and PC3 cells
were then tested to determine whether they would
respond proliferatively to either CCL2 or CCL5. PC3
cells failed to proliferate in response to the same levels
of the same two cytokines (data not shown). However,
as shown in Figure 6, treatment of N15C6 cells with
both of these cytokines elicited a modest but reprodu-
cible proliferative response at levels 20–40% above that
achieved in the absence of cytokine. Although N15C6
cells proliferated in response to HH T-lymphocytes
(Fig. 5A), which secreted high levels of CCL5 (Table II),
they had failed to proliferate in response to dHL-60N
(Fig. 3D),which secreted high levels of CCL2 andCCL5
(Table II), or to dHL-60M (Fig. 3D),which secreted high
levels of CCL2 (Table II). These data suggested that,
although particular cytokines may promote prostate
epithelial cell proliferation in isolation in vitro, this
effect may be tempered or abrogated by opposing
endogenous (epithelial) or exogenous (e.g., leukocytic
or stromal) secreted factors in vivo.
DISCUSSION
The studies reported here were intended to test
the hypothesis that leukocytes associated with either
acute or chronic inflammation potentially attracted to
The Prostate
Fig. 5. Prostate epithelial cells and T-lymphocytes promote
mutualproliferation.A:Theproliferationof transformedPC3(black
diamonds) andLNCaP (graydiamonds) orN15C6 (black squares) or
BPH-1 (gray squares) non-transformedprostate epithelial cellswas
measuredafter 24hrexposure toCD8þMolt-3 (left) orCD4þHH
(right)T-lymphocytes,or vehicle.PC3cellsproliferatedsignificantly
better in response to the presence of CD8þMolt-3 cells, whereas
PC3, N15C6, and BPH-1 cells proliferated significantly better in
response to the presence of CD4þ HH cells (*P< 0.05).B: CD8þ
Molt-3T-lymphocytesremainedviableandproliferatedsignificantly
betterinthepresenceofPC3(blackdiamonds)andLNCaP(graydia-
monds) transformed or N15C6 (black squares) or BPH-1 (gray
squares) non-transformed prostate epithelial cells than in the
absence ofprostate cells (white squares) (left), whereas CD4þHH
T cells remained viable and proliferated significantly better in the
presenceofPC3(blackdiamonds)andLNCaP(graydiamonds)trans-
formed or BPH-1 (gray squares) non-transformedprostate epithe-
lialcells thanintheabsenceofprostatecells (whitediamonds)(right)
(*P< 0.05).







dHL-60M 401 (7.0) 352 (73.5) 775 (41.7)
dHL-60N 8.5 (0.7) 272 (28.3) 151 (17.7)
HL-60 68 (1.4) 52 (4.2) 70 (2.8)
Molt-3 0 0 3 (0.7)
HH 432 (21.2) 0 4 (0.0)
Media 0 0 5 (0.7)
pg/ml/million cells (standard deviation from the mean).
Fig. 6. CCL2andCCL5promotetheproliferationofN15C6pros-
tate epithelial cells. N15C6 treated with vehicle (0) or increasing
doses of CCL2 (A) or CCL5 (B) for 24hr proliferate to levels
20 ^ 40% above that achieved with vehicle. PC3 cells did not
proliferateinresponse to the sameconditions (not shown).
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the prostate consequent to aging or tumorigenesis may
act to promote the abnormal cellular proliferation
associated with BPH and PCa. Previous studies from
our laboratory and others revealed that multiple
leukoattractant cytokines, including CXCL1, CXCL2,
CXCL5, CXCL6, CXCL8, CXCL12, CCL2, and CCL5,
were secreted by aging primary prostate stromal
fibroblasts [6–8,29]. Such data are consistent with the
idea of a ‘‘stromal address code’’ that attracts and
trafficks multiple leukocytic cells types to the aging
prostate [30]. We have also showed that prostate
epithelial cells secrete some of these same chemokines
[6–8]. Therefore, cytokine secretion by both prostate
stromal and epithelial cells could serve as leukoattrac-
tants for various cells involved in both acute and
chronic inflammatory responses. Moreover, all of the
aforementioned cytokineshavebeen shown topromote
the proliferation of both prostate epithelial and stromal
cells [6–8,29]. This suggests that the secretion of the
cytokines by prostate stromal cells, epithelial cells, or
infiltrating leukocytes could serve as growth factors to
promote the proliferation of all of these cell types in the
prostate.
Data reported in this study showed that non-trans-
formed N15C6 and BPH-1, transformed LNCaP and
PC3 cells, primary prostate stromal fibroblasts and
dHL-60N secrete the neutrophilic chemokines CXCL5
and CXCL8 at levels sufficient to promote dHL-60N
migration and sequestration.Moreover, data presented
here suggested that one or more CXCR2 agonists
mediating dHL-60N migration were likely secreted at
higher levels by PC3 compared to N15C6 cells.
Previous studies from our laboratory showed that
PC3 cells secreted the neutrophilic CXCR2 agonist
CXCL5 at levels an order of magnitude higher than
N15C6 cells [7], while data presented here shows that
PC3 cells also secrete higher levels of CXCL8 than
N15C6 cells. Previous data from our laboratory also
showed that primary and metastatic prostate tumors
expressed significantly higher levels of CXCL5 than
normal benign or hyperplastic glands, while Murphy
et al. reported similar data for CXCL8 expression in the
prostate [7,31]. Other studies have reported that the
majority of proteins comprising corpora amylacea and
calcified amylacea are actually specific to neutrophil
granules, and suggests that prostate-infiltrating neu-
trophils may contribute to the etiology of prostate
carcinogenesis [32]. Thus, secretion of neutrophilic
chemokines, especially by PCa cells, may account for
histological evidence for neutrophilic infiltration asso-
ciatedwithmalignant glands in the prostate [5,7,32,33].
Further, both neutrophilic chemokines secreted by PCa
cells and leukocytes differentiated along a neutrophilic
lineage preferentially promote the proliferation of
malignant prostate epithelial cells [7,31,34,35]. Taken
together, these data suggest that leukocytes associated
with acute inflammatory responses are attracted to the
prostatic microenvironment and may play a role in
prostate carcinogenesis.
ELISA showed that none of the prostate epithelial
cells tested appreciably secreted a major macrophilic
chemokine, CCL2. However, both dHL-60N and dHL-
60M cells terminally differentiated along neutrophilic
and macrophagic lineages, respectively, secreted high
levels of CCL2, as did the primary prostate fibroblast
cells. These data suggest that infiltrating neutrophils
and macrophages, as well as the prostatic stroma, may
provide a strongmacrophilic environment. As recently
reviewed by Guruvayoorappan [36], tumor-associated
macrophages (TAMs) have been observed as diffusely
distributed throughout tumors, within tumor zones
and tumor edges, aroundductal areas, and in the tumor
stroma, yet a role for TAMs in cancer progression is
controversial. Nevertheless, immunohistochemical
studies have demonstrated that patients with a high
TAM volume density had a significantly shorter
median PCa specific survival time than patients with
lower TAM volume density, suggesting that macro-
phage infiltration is associated with prostate tumor
growth [37]. Moreover, studies using mouse models
have shown that systemic administration of anti-CCL2
neutralizing antibodies significantly retarded prostate
tumor growth and attenuated CD68þ macrophage
infiltration in vivo, which was accompanied by a
significant decrease in microvascular density, suggest-
ing that CCL2-mediated macrophagic infiltration con-
tributed to PCa [38]. These studies are consistent with
data reported here, that both LNCaP and PC3 trans-
formed PCa cell lines responded proliferatively to
dHL-60Mcells terminally differentiated along amacro-
phagic lineage. Taken together, these data suggest
that monocytic/macrophagic cells may be attracted
to the prostaticmicroenvironment and can promote the
proliferation of transformed prostate epithelial cells,
thus, may promote prostate tumor growth.
Studies described here showed that primary pros-
tate stromal fibroblasts secrete proteins chemotactic for
primary T-lymphocytes (PBMCs) as well as immortal-
ized CD4þ and CD8þ T-lymphocyte cell lines. Both
non-transformed and transformed prostate epithelial
cells also secrete proteins chemotactic for immortalized
T-lymphocytes. Although many chemotactic proteins
are secreted in common by prostate stromal fibroblast
and epithelial cells, some are exclusively secreted by
stromal fibroblasts. In particular, prostate stromal
fibroblasts, but not epithelial cells, secrete CXCL12
[6,8] (Table I). CXCL12 is a known leukoattractant for
T-lymphocytes, which express the major cognate
receptor for this chemokine, CXCR4 [39]. Other
leukoattractant protein secreted in commonbyprostate
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stromal fibroblasts and epithelial cells include CCL2,
CCL5, and CXCL8 (Table I). Using modified Boyden
chamber assays similar to those used in the current
study, Zang et al. [40] showed that T-lymphocytes
migrated in response to CCL2, CCL5, and CXCL8 at
levels of 0.1–1.0 ng/ml, which are similar to those
shown here secreted by prostate epithelial cells
(Table I). The receptors for these chemokines—CCR5
for CCL2 and CCL5, CXCR2 for CXCL8 and CXCR4 for
CXCL12—are all robustly expressed by T-lymphocytes
[39–41]. Another observation from the current study is
that the proliferation of HH andMolt-3 T-lymphocytes
was promoted by the presence of prostate epithelial
cells (with the exception that HH cells did not
proliferate in the presence of N15C6 cells). Taken
together, these studies suggest that several cytokines
and chemokines secreted by either or both prostate
stromal fibroblasts and epithelial cells may encourage
T-lymphocyte infiltration, survival, and proliferation.
If so, the prostate, especially the more secretory aging
prostate, may disrupt homeostatic mechanisms that
normally function to regulate T-lymphocyte localiza-
tion and population size. T-lymphocyte numbers are
tightly regulated in vivo such that clonal expansion of
CD8þ cells during the course of viral infection is
followed by an equivalent contraction in cell number
upon resolution of the infection [42,43]. Apoptosis-
driven T-cell contraction can be suppressed by CCL2,
which has been shown to promote T-cell survival,
especially antigen-activated CD8þ T cells [44]. Nano-
molar levels of CCL5 stimulate T-lymphocyte prolife-
ration and cytokine production, whereas higher
micoromolar levels results in CCL5 oligomerization
and T cell apoptosis [45]. Thus, the expression of low
levels of both CCL2 and CCL5 by prostate epithelial
and/or aging stromal fibroblast cells may function to
promote T-lymphocyte sequesteration and prolife-
ration in the prostate.
The studies reported here also showed that predom-
inantly CD8þMolt-3 cells promote the proliferation of
malignant PC3 prostate epithelial cells, whereas CD4þ
HH cells promote the proliferation of PC3 as well as
non-transformed N15C6 and, to a lesser extent, BPH-1
prostate epithelial cells in vitro. These observations
suggest that T-lymphocytic infiltration in the prostate
may contribute to the overly proliferative phenotype
characteristic of both BPH and PCa in vivo. Recent
work reported by Ebelt et al. [46] showed that
lymphocytic infiltrate in human prostate tissues was
distributed in a dispersed pattern in hyperplastic
epithelium but as peri-tumoral clusters in malignant
tissues. The T-lymphocyte subsetsmost often observed
wereCD3þ andCD4þ, with fewCD8þ cells noted [46].
The observation of CD4þ, rather than CD8þ, cells
reflects a growing, although imperfect, consensus that
tumor infiltration by CD8þ T cells predicts a positive
outcome, while CD4þ cells predict a negative outcome
[47]. Of note, the CD8þ Molt-3 T-lymphocytic cells
used in the current study failed to promote prostate
epithelial cell proliferation to the extent observed for
the CD4þHH T-lymphocytic cells, an observation that
is consistent with potential differences in anti-tumor
activities for CD8þ versus CD4þ effector T cells.
It is likely that the tissue microenvironment within
the human prostate in vivo is complex and comprises
diverse interactions between multiple cell types.
Though based on a simple model system, the in vitro
studies pursued here illustrate some aspects of this
complexity. For example, data described here showed
that conditioned media from PF1 primary prostate
stromal fibroblasts modulated the migration of neu-
trophilic dHL-60N and macrophagic dHL-60M cells
towards prostate epithelial cells. This modulation
was neither entirely agonistic nor antagonistic, but
depended upon the identity and, likely, the secretome
of the epithelial component of the microenvironment.
Other data showed thatN15C6 cells failed toproliferate
in response to dHL-60N or dHL-60M cells even though
both leukocytic cell lines secreted robust levels of CCL2
and CCL5, two cytokines that separately induced
proliferative responses from N15C6 cells. As with the
stromal/epithelial interactions described above, this
data suggests that interactions between leukocytic and
prostate epithelial cells may be agonistic or antago-
nistic, with the exact relationship likely dependent
upon themedley of secreted factors that act to stimulate
or repress cellular proliferation in theprostate. Thedata
reported here also demonstrated that all of the
leukocytic cell types tested—neutrophilic, macropha-
gic, and lymphocytic—stimulated the proliferation of
malignant prostate epithelial cells, but only lympho-
cytic cells clearly stimulated the proliferation of both
transformed and non-transformed prostate epithelial
cells. These data suggest that, during the course of
tumorigenesis, PCa cells may acquire the ability to
respond proliferatively to a host of cytokines secreted
by immune cells, an ability that is not developed innon-
transformed cells. Alternatively, this data may suggest
that non-transformed cells successfully repress pro-
proliferative signals from inflammatory cells, and that
this ability may be lost in cancer cells.
CONCLUSIONS
In conclusion, the studies reported here using an
in vitro model system designed to partially mimic the
prostate tissue microenvironment provide initial infor-
mation regarding leukocytic trafficking to the prostate
and demonstrate that inflammatory cells can selec-
tively promote the proliferation of non-transformed or
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transformed prostate epithelial cells. These studies are
consistent with differential role(s) for inflammatory
infiltrate in the etiologies of benign and malignant
proliferative disease in the prostate. The results of these
studies warrant the development of in vivo models to
accurately recapitulate interactions between inflamma-
tory infiltrate, prostatic stroma (including fibroblastic,
myofibroblastic, and endothelial cells) and glandular
prostatic epithelium that may contribute to the devel-
opment of benign and malignant proliferative disease
in the prostate.
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